André da Silva: Stroke Is Not an Explosion – It’s Often a Silent Loss of Blood Flow
André da Silva, Scrub Nurse at American Hospital Dubai, shared on LinkedIn:
”Most people imagine a stroke as a sudden ‘explosion’ in the brain.
In reality, the most common type is the opposite – a silent loss of blood flow.
Stroke is broadly divided into two entities, each requiring fundamentally different management:
- Ischemic stroke (~85–87%)
An arterial occlusion interrupts cerebral perfusion, leading to rapid neuronal death — estimated at nearly 2 million neurons per minute.
Management: urgent reperfusion (e.g., thrombolysis with tPA or mechanical thrombectomy).
- Hemorrhagic stroke (~13–15%)
Vessel rupture causes intracranial bleeding, increasing pressure and damaging surrounding tissue.
Management: hemostasis, blood pressure control, and neurosurgical intervention when indicated.
Clinically, both can present identically:
- facial asymmetry
- limb weakness
- speech disturbance
- sudden neurological deficit
Neuroimaging: typically non-contrast CT – is the critical first step to differentiate them.
Treating blindly is not an option; the wrong intervention can be catastrophic.
This is why in stroke care, time is brain – and precision is just as vital as speed.
The intersection of neurology and neurosurgery remains one of the most time-sensitive and decision-critical areas in medicine – where seconds shape outcomes.
What concept in medicine changed the way you think about patient care?”

Stay updated with Hemostasis Today.
-
Nov 20, 2026, 17:27Adam Bryant: Great Science, Valuable Connections and a Wonderful Haematology Community at Blood 2026
-
Nov 20, 2026, 17:25Gurpreet Kaurr: Scientific Discussions, New Perspectives and Inspiration at HAEMATOCON 2026
-
Nov 20, 2026, 17:24Bispecific FVIIIa-Mimetic Antibodies in Haemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Nov 20, 2026, 17:23Khalid Rehman: Psychosocial Burden Among Caregivers of Patients with Beta-Thalassemia Major in Pakistan
-
Nov 20, 2026, 17:20Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP
-
Nov 20, 2026, 17:19Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop
-
Nov 20, 2026, 17:18WFH Opens Public Comment on Draft Guidelines for Hemostatic Agents and Prophylaxis
-
Nov 20, 2026, 17:18Ketan Asawale: Consensus on the Management of Cancer-Associated Thrombosis in India
-
Nov 20, 2026, 17:16Ajay Samkaria: The Evolution of Hemostasis Diagnostics with the ACL TOP 70 Series